L3VLUP
ProSign in

NVAX in the 13F filings

Novavax Inc · CUSIP 670002401

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q2 2023
Quarter end
30 Jun 2023
the date the book describes
Filed
14 Aug 2023
latest of these filings; the earliest 28 Jul 2023
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 1 listed it in both
Shares listed
1,039,123
combined, among listed positions
Reported value
$7.7m
combined, at the quarter end

Managers listing NVAX in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Coatue Management LLC1,039,123$7.7munder 0.1%Trimmed-726,93614 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

035810202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
NVAX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20207$143mn.a.n.a.
Q3 20206$258mn.a.n.a.
Q4 20204$221mn.a.n.a.
Q1 202110$1.5bnn.a.n.a.
Q2 20218$1.6bnn.a.n.a.
Q3 20214$609mn.a.n.a.
Q4 20214$399mn.a.n.a.
Q1 20225$121mn.a.n.a.
Q2 20226$148mn.a.n.a.
Q3 20223$34mn.a.n.a.
Q4 20223$8.0mn.a.n.a.
Q1 20232$12mn.a.n.a.
Q2 20231$7.7mn.a.n.a.
Q4 20231$7.3m10
Q1 20242$13m10
Q2 20246$163m51
Q3 20245$129m23
Q4 20242$520k02
Q1 20252$25m10
Q2 20252$24m00
Q3 20252$40m10
Q4 20251$1.3m1313
Q1 20262$31m1712
Q2 20261$36m1020

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

NVAX and GILD →NVAX and AMGN →NVAX and ARGX →Choose a stock to compare with NVAX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own NVAX, latest filings →Back to the 13F Explorer →